Hester Bios Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
No
Order
No
Capex
No
0 of 5 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Target to achieve Rs.600 Crores revenue in approximately 3 years through current capacity in India, Nepal, and Africa (Rajiv Gandhi).
- African subsidiary in Tanzania expected to ramp up to $25 million sales in 4-5 years, leveraging existing capacity (Rajiv Gandhi).
- Poultry vaccine sales showing recovery, following an industry downturn; expectation of industry improvement from current low levels (Rajiv Gandhi).
- Health products growing rapidly (60% increase quarter-on-quarter) though currently smaller base; focus on increasing cycles of health products to drive EBITDA growth (Rajiv Gandhi).
- Pet care business is a sunrise industry in India, growing at around 20% YoY, with significant future potential due to increase in pet ownership (Rajiv Gandhi).
- Immunization programs like Government of India’s PPR program (Rs.40 Crores tender) expected to boost sales (Priya Gandhi).
- Overall optimistic about revenue growth higher than last year with improved bottom lines.
See what Hester Bios management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- Currently, Hester Biosciences has no plans for taking additional debt or loans.
- The company is at its highest borrowing level, but the debt is expected to reduce over time.
- No additional capital expenditure (capex) is required for ongoing projects at present.
- Approximately Rs.10-12 Crores payable for existing capital creditors related to current projects.
- Any new capital expenditure or fund raising would be a different situation, but currently, they are fully covered for expansions with invested capital.
- Grants related to specific projects may continue to come but not considered as regular fundraising.
- Overall, no planned fundraising through debt or equity in the near term based on management comments.
See what Hester Bios management said on order book — free account, 30 seconds.
Capex plans
No- No significant additional capex is currently planned for ongoing projects; only Rs.10-12 Crores payable for existing capital creditors.
- Fill-finish facility under construction expected to commission within ~60 days; this will double vaccine capacity in India.
- BSL-III laboratory (COVID bulk antigen manufacturing) facility being repurposed post-COVID.
- Capital already invested covers current expansion potentials: Rs.50 Crores in Nepal, $25-30 million (~Rs.200 Crores) in Africa, and an additional Rs.200 Crores capacity potential in India.
- Any new capital investment would be situational and unlikely at this moment.
- Grants related to specific projects (like COVID) may continue but are project-specific, not recurring.
- Overall, the company is capital-ready to support growth without needing substantial new capex immediately.
Track Hester Bios — get its next earnings analysis in your feed
Margin guidance
Category 3- Hester Biosciences aims to restore and improve margins to previous levels despite current challenges, combining both vaccine and health product sales.
- Management is optimistic about revenue growth, expecting a higher growth rate this year compared to last year.
- The poultry division is anticipated to recover from its current low phase, showing improvement quarter-on-quarter.
- Health products and pet care business are viewed as growth drivers, with the pet segment growing ~20% YoY, faster than poultry or animal healthcare.
- New immunization programs like the Government's PPR vaccination tender (Rs.40 Cr order) will boost sales in the coming year.
- African and Nepal subsidiaries plan gradual capacity ramp-ups, targeting $25M revenue in Africa over 4-5 years.
- Overall, the company expects sales to increase, profit margins to improve, and sustainable growth over the next 3 years with a target of Rs.600 Cr revenue expansion.
Order book
No- Hester Biosciences currently has orders in hand worth around Rs.15 Crores in Nepal.
- Various tenders are in process in Nepal, indicating ongoing order activity.
- There is a mention of unexecuted orders for the PPR vaccine, due to a shift in government focus to lumpy skin disease, expected to be fulfilled soon.
- Immunization programs impact quarterly sales based on the timing of government orders, causing some variability in order execution.
- The company is also targeting the domestic market alongside tender-based business, with increasing revenues expected from this segment.
How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Hester Bios rank in Pharmaceuticals & Biotechnology?
Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Hester Bios's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…